Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03710707 · ClinicalTrials.gov registry record · Phase 1
Study to Evaluate DNL201 in Subjects With Parkinson's Disease
A Phase 1 study, sponsored by Denali Therapeutics.
- Completed
- Registry status
- Phase 1
- Development phase
- 29
- Enrollment target
NCT03710707 is a Phase 1 study that has completed, run by Denali Therapeutics. The registered enrollment target is 29 participants.
The verdict
NCT03710707, a Phase 1 study, has completed, sponsored by Denali Therapeutics.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 29 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of multiple oral doses of DNL201 in subjects with Parkinson's disease.
Interventions
- DRUG Placebo
- DRUG DNL201
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 29 participants |
| Start Date | 2018-12-04 |
| Est. Completion | 2019-12-06 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03710707
The ClinicalTrials.gov registry entry for NCT03710707 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 29 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Denali Therapeutics, which has 12 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT03710707 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03710707 about?
NCT03710707 is a clinical study titled "Study to Evaluate DNL201 in Subjects With Parkinson's Disease". The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of multiple oral doses of DNL201 in subjects with Parkinson's disease.
What is the current status of trial NCT03710707?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 29 participants. The study started on 2018-12-04. Estimated completion is 2019-12-06.
What interventions are being tested in trial NCT03710707?
The interventions under investigation include: Placebo (DRUG), DNL201 (DRUG).
Who is sponsoring clinical trial NCT03710707?
This trial is sponsored by Denali Therapeutics, which has 12 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.